Clinical Trials

4 trials
RecentStart dateEnrollment
Nelfinavir × Plasma cell × Clear all
NCT01164709 2019-05-15

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Swiss Cancer Institute

Phase 1 Completed
18 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell